AONC (AON) Forward P/E Multiple

Official company branding of American Oncology Network, Inc. (AONC)

American Oncology Network (AONC) relies on a sovereign cycle, rendering it a defensive asset regardless of macroeconomic conditions. The AONC clinic network provides regional access to high-tech therapy, earning the trust of patients. The company's expected P/E ratio demonstrates value dynamics relative to earnings, with the current parameter standing at 0.00. The integration of AI diagnostics and software into a single B2B ecosystem creates total physician dependency on the platform.

aoncology.com - AONC Forward P/E Multiple (period 02/21/2024 - 08/04/2024)

Summary analytical data breakdowns for American Oncology Network (AONC)

Comprehensive company analysis:AONC American Oncology Network
Brand item of AON

Fundamental asset screening requires an accurate valuation of a business relative to its future cash flows. By analyzing the forward P/E ratio of American Oncology Network (AONC), an investor compares the market price with expected net income, which allows for an assessment of the efficiency of scaling the American Oncology Network (AONC) clinic network through procurement optimization and the centralization of IT infrastructure to reduce operating expenses.

Competitors of American Oncology Network

Forward P/E Multiple ONC|HALO (Halozyme Inc.) - Future Price to Earnings Multiple|Forward P/E Multiple RVMD (revmed.com)|AAPG - Projected Price to Earnings|CGON: Projected Price to Earnings|URGN - Forward P/E Multiple|Bicara Bio (BCAX) - Future Price to Earnings|Personalis Corp - Future Price to Earnings Multiple|ERAS (Erasca Inc) - Forward P/E Multiple|Projected Price to Earnings Ratio Delcath Systems, Inc. DCTH|Projected Price to Earnings YMAB (Y-mAbs Corp)|Forward P/E Multiple Aura Bio (AURA)|Forward P/E Multiple CADL (Candel Therapeutics Inc.)|ARAY - Projected Price to Earnings|SLS - Future Price to Earnings|Actuate Therapeutics - Market Cap to Future Earnings Ratio|CTOR: Forward P/E Multiple|TuHURA (HURA) - Forward P/E Multiple|TARA (Protara Therapeutics Inc) - Forward P/E Multiple|FATE: Future Price to Earnings Multiple|Forward P/E Multiple WHWK|TCRX (TScan) - Future Price to Earnings Multiple|Future Price to Earnings Champions Oncology, Inc. CSBR|XBIT - Projected Price to Earnings|CEL-SCI - Forward P/E Multiple|OSTX - Forward P/E Multiple|Radiopharm Theranostics Limited (RADX) - Future Price to Earnings|ARTV - Market Cap to Projected Earnings|Projected Price to Earnings ANL|Future Price to Earnings VERU|Forward P/E Multiple TPST|XLO: Price to Expected Earnings Ratio|Forward P/E Multiple RENB (Renovaro Inc.)|Mural Bio (MURA) - Projected Price to Earnings Ratio|Kairos Pharma Ltd - Forward P/E Multiple|Price to Expected Earnings Ratio OKUR|CytoMed Therapeutics Limited (GDTC) - Future Price to Earnings|CRIS - Market Cap to Projected Earnings|Projected Price to Earnings APLM|Tharimmune (THAR) - Market Cap to Projected Earnings|Projected Price to Earnings ADVB (Advanced Biomed Inc.)|Genprex - Price to Future Earnings Ratio|Forward P/E Multiple CLDI (Calidi Biotherapeutics, Inc.)|SBFM - Projected Price to Earnings|Xenetic Bio - Forward P/E Multiple|SLRX - Forward P/E Multiple|PPBT: Forward P/E Multiple|Price to Future Earnings Ratio BGNE|Projected Price to Earnings CKPT|Future Price to Earnings ELEV|Forward P/E Multiple ICAD|Forward P/E Multiple Ikena Oncology Inc. (IKNA)|Forward P/E Multiple NTBL (Notable Labs Ltd)|Market Cap to Projected Earnings Viracta Therapeutics (VIRX)|MOR: Projected Price to Earnings|NAYA (NAYA Bio) - Price to Future Earnings Ratio|AAPGV: Forward P/E Multiple